Theognosia Vergou1, Christina Antoniou1
1Psoriasis Clinic, Department of Dermatology, University of Athens, A. Sygros Hospital, Athens, Greece.
Corresponding Author: Theognosia vergou, Psoriasis Clinic, Department of Dermatology, University of Athens, A. Sygros Hospital, Athens, Greece, Tel: 210 7265100; E-Mail: firstname.lastname@example.org
Received Date: 09 Jan 2016
Accepted Date: 23 Jan 2016
Published Date: 26 Jan 2016
Copyright © 2016 Vergou T
Citation: Vergou T and Antoniou C. (2016). New Therapeutic Agents for Psoriasis. Mathews J Dermatol. 1(1): 002.
During the last decades, inside and deep knowledge of the pathogenesis of psoriasis, has led to new therapeutic agents for the treatment of the disease, resulting in a revolutionary and holistic therapeutic approach. For many years the anti-TNF agents as well as the agents that target the IL12/23 pathway, have changed the armamentarium of drugs in the treatment of psoriatic disease with excellent results. In the present article we will present all available data about new agents that are under development for the treatment of psoriasis, like anti-IL17 and anti-IL23 biologics, as well as the small molecules, like JAK inhibitors and inhibitors of phosphodiesterase-4 (PDE4).
psoriasis; IL-17 inhibitors; IL-23 inhibitors; PDE4 inhibitors; small molecules; JAK inhibitors.